|Bid||11.53 x 1100|
|Ask||11.86 x 1100|
|Day's Range||11.51 - 11.72|
|52 Week Range||9.07 - 17.05|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Joshua Drumm, VP, Investor Relations. Please go ahead. Joshua Drumm: […]
The preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide.
The U.S. health regulator did not find any misconduct at clinical sites managed by Care Access for Pfizer and French partner Valneva's trial of a Lyme disease vaccine candidate, the contract research firm said on Wednesday. Pfizer and Valneva said in February they will stop testing the vaccine in roughly half of U.S. patients in a late-stage study, due to a breach of clinical trial guidelines by a third-party contractor. The vaccine for Lyme disease, which causes infections that are transmitted to humans through ticks, has shown a "strong immune response" in a mid-stage study in both children and adolescents a month after a booster dose.